Telix Executive and Leadership Team

Darren Smith, the Group Chief Financial Officer at Telix, oversees the company's financial strategy, planning, and reporting. Smith manages all aspects of financial operations, including capital allocation, investor relations, and fiscal management to support Telix's global expansion and research initiatives. This executive role is pivotal in securing funding, managing budgets, and ensuring the financial health of the organization as it commercializes its innovative radiopharmaceutical products. By providing strategic financial guidance, Darren Smith enables Telix to invest in critical R&D, expand its market presence, and navigate the complexities of public listings on exchanges like the ASX and Nasdaq. The Group Chief Financial Officer's expertise is crucial for driving sustainable growth and maximizing shareholder value.

Darren Patti, the Group Chief Operating Officer at Telix, manages the company's global operational execution and supply chain logistics. Patti directs the day-to-day business activities, ensuring efficient production and distribution of Telix's radiopharmaceutical products across international markets. This leadership position involves optimizing manufacturing processes, maintaining high standards of quality control, and overseeing the complex regulatory compliance required for pharmaceutical operations. By streamlining operational workflows, Darren Patti enhances the company's capacity to deliver critical cancer imaging and therapeutic agents to patients worldwide. The Group Chief Operating Officer's strategic oversight ensures that Telix can scale its operations effectively to meet growing global demand, supporting the company's mission to provide innovative theranostic solutions.

Craig Ulrick, the Chief Information Officer at Telix, directs the company's global information technology strategy and infrastructure. Ulrick oversees the implementation and management of all IT systems, ensuring robust cybersecurity measures and data integrity across the organization. This leadership role involves architecting scalable technology solutions that support Telix's rapid growth and complex operational needs in the biopharmaceutical sector. By optimizing digital workflows and enhancing internal communication platforms, Craig Ulrick drives operational efficiency and facilitates seamless collaboration among global teams. The Chief Information Officer's focus remains on leveraging technology to accelerate the development and commercialization of Telix's diagnostic and therapeutic radiopharmaceuticals, ensuring compliance with stringent regulatory requirements and supporting the company's mission to improve cancer care.

Paul Schaffer, the Chief Technology Officer at Telix, spearheads the technological innovation and development of the company's radiopharmaceutical pipeline. Schaffer guides the research and development efforts, focusing on advancing theranostic agents for cancer imaging and treatment. This critical role involves translating scientific discoveries into viable commercial products, ensuring the technological feasibility and scalability of Telix's therapeutic and diagnostic solutions. Overseeing the integration of advanced technologies, Paul Schaffer ensures that the company remains at the forefront of molecularly targeted radiation. By driving innovation in radiochemistry and manufacturing processes, Schaffer directly supports the expansion of Telix's product portfolio in urologic oncology, neuro-oncology, and other key areas, reinforcing the company's commitment to pioneering new cancer therapies.

David Cade, the Chief Medical Officer at Telix, leads the company's clinical development and medical affairs strategy. Cade directs the design and execution of clinical trials for Telix's diagnostic and therapeutic radiopharmaceuticals, ensuring adherence to global regulatory standards and scientific rigor. This vital role involves translating the company's scientific advancements into effective patient treatments, focusing on key oncology areas such as prostate, kidney, and brain cancers. By overseeing the clinical evaluation of theranostic agents, David Cade plays a crucial part in bringing innovative cancer therapies to market. The Chief Medical Officer's medical expertise guides the strategic direction of Telix's pipeline, aiming to improve diagnostic accuracy and therapeutic outcomes for patients facing serious oncological conditions.